Thursday, February 27, 2025 9:53:19 AM
Outstanding Shares
02/26/2025 1,365,403,347 (+2,124,525 = 39,496,381 YTD)
02/25/2025 1,363,278,822 (+1,074,344 = 37,371,856 YTD)
02/24/2025 1,362,204,478 (+5,676,772 = 36,297,512 YTD)
02/20/2025 1,356,527,706 (+1,346,754 = 30,620,740 YTD)
02/11/2025 1,355,180,952 (+787,711 = 29,273,986 YTD)
02/10/2025 1,354,393,241 (+5,480,170 = 28,486,275 YTD)
02/06/2025 1,348,913,071 (+1,111,112 = 23,006,105 YTD)
02/05/2025 1,347,801,959 (+2,782,078 = 21,894,993 YTD)
01/30/2025 1,345,019,881 (+816,327 = 19,112,915 YTD)
01/28/2025 1,344,203,554 (+3,829,410 = 18,296,588 YTD)
01/27/2025 1,340,374,144 (+1,840,019 = 14,467,178 YTD)
01/24/2025 1,338,534,125 (+1,620,400 = 12,627,159 YTD)
01/23/2025 1,336,913,725 (+1,815,694 = 11,006,759 YTD
01/21/2025 1,335,098,031 (+1,153,105 = 9,191,065 YTD)
01/15/2025 1,333,944,926 (+4,319,435 = 8,037,960 YTD)
01/13/2025 1,329,625,491 (+1,022,428 = 3,718,525 YTD)
01/06/2025 1,328,603,063 (+2,696,097 = 2,696,097 YTD)
01/02/2025 1,325,906,966
02/26/2025 1,365,403,347 (+2,124,525 = 39,496,381 YTD)
02/25/2025 1,363,278,822 (+1,074,344 = 37,371,856 YTD)
02/24/2025 1,362,204,478 (+5,676,772 = 36,297,512 YTD)
02/20/2025 1,356,527,706 (+1,346,754 = 30,620,740 YTD)
02/11/2025 1,355,180,952 (+787,711 = 29,273,986 YTD)
02/10/2025 1,354,393,241 (+5,480,170 = 28,486,275 YTD)
02/06/2025 1,348,913,071 (+1,111,112 = 23,006,105 YTD)
02/05/2025 1,347,801,959 (+2,782,078 = 21,894,993 YTD)
01/30/2025 1,345,019,881 (+816,327 = 19,112,915 YTD)
01/28/2025 1,344,203,554 (+3,829,410 = 18,296,588 YTD)
01/27/2025 1,340,374,144 (+1,840,019 = 14,467,178 YTD)
01/24/2025 1,338,534,125 (+1,620,400 = 12,627,159 YTD)
01/23/2025 1,336,913,725 (+1,815,694 = 11,006,759 YTD
01/21/2025 1,335,098,031 (+1,153,105 = 9,191,065 YTD)
01/15/2025 1,333,944,926 (+4,319,435 = 8,037,960 YTD)
01/13/2025 1,329,625,491 (+1,022,428 = 3,718,525 YTD)
01/06/2025 1,328,603,063 (+2,696,097 = 2,696,097 YTD)
01/02/2025 1,325,906,966
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
